Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
A NyhlénI Nilsson-Ehle

Abstract

To determine the impact of neutropenia on the pharmacokinetics of meropenem, 14 patients with fever and neutropenia were given 1 g of meropenem i.v. every 8 h as an infusion over 30 min. The volume of distribution (16.2 l/1.73 m2) and the nonrenal clearance [75 ml/(min x 1.73 m2)] in this group were significantly increased compared to healthy subjects studied previously with identical techniques. The kinetic study was repeated when the patients had a normal temperature and a raised neutrophil count; most kinetic variables did not differ from the findings on the first day of treatment. The pharmacokinetic profile of meropenem in febrile neutropenic patients differs from earlier findings in healthy subjects. Considering these data and known minimum inhibitory concentration values for common pathogens, meropenem administered every 6 to 8 h seems an appropriate regimen in patients with febrile neutropenia. The shorter time interval may be used for treatment of Pseudomonas infection.

References

Dec 1, 1992·Antimicrobial Agents and Chemotherapy·W A Craig, S C Ebert
Jul 1, 1992·Antimicrobial Agents and Chemotherapy·B Ljungberg, I Nilsson-Ehle
Feb 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I Nilsson-EhleS R Norrby
Jun 1, 1990·The Journal of Antimicrobial Chemotherapy·P J Wu, D M Livermore
Sep 1, 1989·The Journal of Antimicrobial Chemotherapy·H L NadlerW Sheikh
Nov 1, 1989·Scandinavian Journal of Clinical and Laboratory Investigation·S E BäckP Nilsson-Ehle
Oct 1, 1988·The Journal of Infectious Diseases·B VogelmanW A Craig
Mar 1, 1988·Antimicrobial Agents and Chemotherapy·G L Drusano
Jan 1, 1988·European Journal of Clinical Pharmacology·B Ljungberg, I Nilsson-Ehle
Oct 1, 1981·Scandinavian Journal of Clinical and Laboratory Investigation·G Granerus, M Aurell
May 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H HanbergerM Nilsson
Mar 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S DaenenM R Halie
Jun 1, 1993·The Journal of Antimicrobial Chemotherapy·I Odenholt-Tornqvist
Jan 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·W Craig
Jan 1, 1995·Scandinavian Journal of Infectious Diseases·F FuentesJ Prieto

❮ Previous
Next ❯

Citations

Jun 29, 2013·Clinical Pharmacokinetics·Tiphaine Goulenok, Bruno Fantin
Feb 19, 2002·International Journal of Antimicrobial Agents·Ruth Kitzes-CohenSylvie Anne De Myttenaere-Bursztein
Sep 12, 2012·Current Opinion in Infectious Diseases·Iain J Abbott, Jason A Roberts
Sep 1, 2006·International Journal of Antimicrobial Agents·Dong-Gun LeeDong-Seok Yim
Jul 6, 2011·International Journal of Antimicrobial Agents·Sutep JaruratanasirikulWibul Wongpoowarak
Dec 16, 2004·The Annals of Pharmacotherapy·Robert E ArianoSheryl A Zelenitsky
Sep 27, 2012·The Annals of Pharmacotherapy·Gary E SteinDaniel H Havlichek
Jun 14, 2005·Journal of Clinical Pharmacology·Robert E ArianoDaniel S Sitar
Sep 4, 2018·British Journal of Clinical Pharmacology·Dagan O LonsdaleJoseph F Standing
Apr 17, 2001·Scandinavian Journal of Infectious Diseases·A NyhlénI Nilsson-Ehle
Jan 16, 2013·Therapeutic Drug Monitoring·Lutz BinderPhilip D Walson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.